Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule


Content of the article

VANCOUVER, British Columbia & SEATTLE – Zymeworks Inc. (NYSE: ZYME), a biopharmaceutical pharmaceutical company that specializes in multifunctional biotherapeutics, today stated, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (“NYSE Rule”), a reward for promoting justice for Mr. Kenneth Galbraith, the new Chairman of Zymeworks, President and Chief Executive Officer.

In accordance with the NYSE Act, Zymeworks approved the following award to Mr. Galbraith as a catalyst for Mr. Galbraith to enter into employment with the Zymeworks: from the date on which his work with Zymeworks began, the procurement process. 500,000 of the company’s common shares (“Options”). The decision has the price of a gymnast for each of the $ 14.97 per share, which is the equivalent of the normal share price of the company on January 14, 2022, and lasts for more than 10 years. Mr. Galbraith’s work with the company began on January 15, 2022 (” Start date”).

Content of the article

The nominations will be presented for four years as follows: (i) 1/4 of the Decisions shall be commemorated in the first year of the Commencement Day and (ii) 1/36 of the remaining Examination shall be finalized. a day of each month following the one-year commemoration of the Commencement Date until all Decisions have been made, according to Mr. Galbraith ‘s continuation. In addition, (i) if there is a change in the management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system management system The management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the management of the system of 100% of the options that he did not use will have sufficient force at the end of his term

The decision was made outside of the Amended and Restated Stock Option and Equity Compensation Plan (“Modern Plans”) under Zymeworks Inc. The Induced Stock Option and Equity Compensation Plan are compliant, but will follow the rules and conditions generally consistent with the contents of the Current Plans except for those to be followed by the NYSE Award.

Ideas for the company Zymeworks Inc.

Zymeworks is a biopharmaceutical medical company dedicated to the next generation of medical products. Zymeworks’ suite therapeutic suit and its well-integrated pharmaceutical engine support the precise engineering of those with the most diverse equipment. Zymeworks’s clinical guide, zanidatamab, and the bispecific antibody’s Hym2 buku HER2 regimen are currently being reviewed in Phase 1, Phase 2, as well as important clinical trials around the world as a way to treat patients with solid tumors that show HER2. Zymeworks ‘second patient, ZW49, is a Bispecific HER2-focused antibody-drug conjugate currently in Phase 1 of clinical development and combines the unique formulation of zanidatamab with Zymeworks’ proprietary ZymeLink ™ link and cytotoxin. Zymeworks is also developing a deep pipeline in oncology (including immuno-oncology agents) and other natural fields. In addition, its therapeutic towers are being supported through technical partnerships with global biopharmaceutical companies. To learn more about our ongoing clinical trials visit www.zymeworksclinicaltrials.com . To learn more about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Check out the starting lineup at businesswire.com: https://www.businesswire.com/news/home/20220115005009/en/

mark

Contacts

Questions for Investor:
Ryan Dercho, Ph.D.
(604) 678-1388
[email protected]

Jack Spinks
(604) 678-1388
[email protected]

Media Queries:
Mary Klem
(604) 678-1388
[email protected]

#distro


Original Article reposted fromSource link

Disclaimer: The website autopost contents from credible news sources and we are not the original creators. If we Have added some content that belongs to you or your organization by mistake, We are sorry for that. We apologize for that and assure you that this won’t be repeated in future. If you are the rightful owner of the content used in our Website, please mail us with your Name, Organization Name, Contact Details, Copyright infringing URL and Copyright Proof (URL or Legal Document) aT spacksdigital @ gmail.com

I assure you that, I will remove the infringing content Within 48 Hours.

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Warner Music Group names 15 new recipients of grants from its $100m social justice fund

The Warner Music Group/ Blavatnik Family Foundation Social Justice Fund (WMG / BFF SJF) has announced its third group of beneficiaries. The new funding promotes the WMG / BFF SJF’s vision of “tackling sustainable discrimination and the realization of the lives of previously disadvantaged and oppressed people,” it said. Warner Music Group announced its release […]

Read More
Business

ECB accounts unveil deep divisions on inflation outlook

Breadcrumb Trail links PMN Business Reporter: Content of the article FRANKFURT – The fall in Euro prices could easily “stabilize” beyond what it wants and why the European Central Bank should keep the door tight, ECB policymakers argued at a key meeting last month, accounts released by the ECB on Thursday showed. The central euro […]

Read More
Business

UnaBiz partners with Kinéis to provide satellite IoT connectivity for Logistic and Transportation

Headquartered in Singapore, UnaBiz is a multinational IoT provider that has delivered more than 1.4 million sensors in 28 countries around the world. The 5-year growth has recently raised US25 million in its Series B funding and is looking to expand its capabilities and create solutions in a number of ways. “Kinéis and UnaBiz are […]

Read More